Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762
Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and
How this was made
The 30-second read
Why it matters
Traders can update models for cash runway, near-term operating burn, and the expected regulatory cadence (FDA meeting request in 3Q26) while monitoring dilution risk from the ATM equity program.
Market read
The filing combines (1) cash and expense trajectory, (2) PH-762 regulatory next-step timing, and (3) capital sourcing via an ATM program, which together can drive small-cap biotech positioning.
What to watch
Cash fell from $21.0M to $13.0M by June 30, 2026, while R&D rose sharply; the ATM program up to $6.36M can create dilution overhang even if runway extends into 2H27.
Background
This is an SEC Form 8-K (Item 2.02) with an exhibit reporting Phio’s 2Q26 financial results and a business update for its lead siRNA program PH-762.
Ticker impact
Phio reported 2Q26 results and said PH-762 Phase 1b documentation is being prepared for FDA submission, with an FDA meeting planned in 3Q26.
Likely modest volatility around biotech risk appetite, with upside bias if investors view the FDA meeting and PH-762 documentation as de-risking, offset by cash burn and ATM overhang.
The filing is a primary disclosure (8-K with exhibit) including cash balance ($13.0M at June 30, 2026), R&D increases, and a stated plan to request an FDA meeting in 3Q26. However, it does not provide new efficacy endpoints or FDA feedback, limiting immediate re-rating certainty.
Market effects
Adds another siRNA/oncology development datapoint emphasizing CMC and nonclinical toxicology buildout ahead of FDA discussions.
Limited direct regional spillover; primarily US small-cap biotech sentiment.
IP actions referenced across US, Canada, and Japan may marginally support broader platform confidence, but no global regulatory decision is disclosed.
Counterpoint
The update highlights process milestones (API, toxicology, documentation prep) but provides no new clinical efficacy or FDA guidance, so the market may discount it as incremental.
Key entities
- companyPhio Pharmaceuticals Corp.
Clinical-stage siRNA biopharmaceutical company advancing INTASYL technology and lead candidate PH-762.
- productPH-762
Lead INTASYL compound evaluated in a Phase 1b intratumoral trial for skin cancers; next steps include FDA meeting request and submission of final documentation.
- financial_agentH.C. Wainwright & Co., LLC
Sales agent for Phio’s at-the-market (ATM) equity offering program.
- regulatorFDA
Phio plans to request an FDA meeting in 3Q26 to discuss next clinical trial design and development strategy.
